Responses
Poster Presentations
Rheumatoid arthritis - other biologic treatment
FRI0251 SIRUKUMAB, an ANTI-IL-6 cytokine monoclonal antibody, leads to improvements in work productivity and general health status in patients with active rheumatoid arthritis refractory to ANTI-TNF therapy: results from the phase 3 SIRROUND-T study
Compose a Response to This Article
Other responses
No responses have been published for this article.